MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 1

[Northerner]

MannKind Corporation (MNKD) today announced that all follow-up visits have been completed for the patients enrolled in Study 171, a Phase 3 clinical study of AFREZZA (insulin human [rDNA origin]) inhalation powder, an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind?s next-generation inhaler. MannKind expects to release data from this study later this summer.

http://pipelinereview.com/index.php...AFREZZA-in-Patients-with-Type-1-Diabetes.html